# EDGAR Filing Document

**Accession Number:** 0001478320
**File Stem:** 0001193125-26-083128
**Filing Date:** 2026-2
**Character Count:** 23773
**Document Hash:** 401b9ad109fc2a45568fe0a453ca8cb0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-083128.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001193125-26-083128

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**EFFECTIVENESS DATE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adaptive Biotechnologies Corp
- **CENTRAL INDEX KEY:** 0001478320
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 270907024
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293879
- **FILM NUMBER:** 26701547

**BUSINESS ADDRESS:**
- **STREET 1:** 1165 EASTLAKE AVE E
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109
- **BUSINESS PHONE:** 206-659-0067

**MAIL ADDRESS:**
- **STREET 1:** 1165 EASTLAKE AVE E
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adaptive TCR Corp
- **DATE OF NAME CHANGE:** 20091209

**As filed with the Securities and Exchange Commission on February 27, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## ADAPTIVE BIOTECHNOLOGIES CORPORATION
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Washington** | **27-0907024** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |
| **1165 Eastlake Avenue East**<br> **Seattle, Washington** | **98109** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan** 

**(Full Title of the Plans)** 

**Chad Robins** 

**Chief Executive Officer** 

**Adaptive Biotechnologies Corporation** 

**1165 Eastlake Avenue East** 

**Seattle, Washington 98109** 

**(206) 659-0067** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Andrew Ledbetter** 

**DLA Piper LLP (US)** 

**701 Fifth Avenue, Suite 6900** 

**Seattle, Washington 98104** 

**Telephone: (206) 839-4800** 

**Facsimile: (206) 839-4801** 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the "Commission") for the purpose of registering an additional 14,943,083 shares of the common stock of Adaptive Biotechnologies Corporation (the "Company"), par value $0.0001 per share ("Common Stock"), issuable under the 2019 Equity Incentive Plan (the "2019 EIP") for which registration statements of the Company on Form S-8 filed with the Commission on July 1, 2019 (File No. [333-232495](http://www.sec.gov/Archives/edgar/data/1478320/000119312519187486/d30595ds8.htm)) and February 14, 2023 (File No. [333-26976](http://www.sec.gov/Archives/edgar/data/1478320/000095017023002798/adpt_-_form_s-8_2023.htm)7) (the "Prior Registration Statements") are effective, as a result of the operation of automatic annual increases provided for therein on January 1, 2024 and January 1, 2026, added 14,943,083 shares of Common Stock. In accordance with Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made a part of this Registration Statement on Form S-8.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Not filed as part of this Registration Statement pursuant to the instructions to Part I of Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

------

**Item 3. Incorporation of Documents by Reference.** 

The following documents filed with the Commission by the Company pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are hereby incorporated by reference in this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm) for the fiscal year ended December 31, 2025 filed with the Commission on February 26, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company's registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1478320/000119312519181757/d739168d8a12b.htm) (File No. 001-38957) filed with the Commission on June 26, 2019 pursuant to Section 12(b) of the Exchange Act, relating to the Company's
Common Stock, including all other amendments and reports filed for the purpose of updating such description.

All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this registration statement (except for any portions of the registrant's current reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this registration statement indicating that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

Not applicable.

**Item 6. Indemnification of Directors and Officers.** 

RCW 23B.08.320 permits a Washington corporation to, through its articles of corporation, eliminate or limit the personal liability of a director to the corporation or its shareholders for monetary damages for conduct as a director, except for the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acts or omissions that involve intentional misconduct by a director or a knowing violation of law by a director;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• conduct violating RCW 23B.08.310 relating to unlawful distributions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any transaction from which the director will personally receive a benefit in money, property or services to which
the director is not legally entitled; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any act or omission occurring prior to the date when the provision in the articles of incorporation eliminating
or limiting liability becomes effective.

RCW 23B.08.510 authorizes a Washington corporation to indemnify an individual made a party to a proceeding because the individual is or was a director against liability incurred in the proceeding if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the individual acted in good faith;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the individual reasonably believed (a) in the case of conduct in the individual's official capacity
with the corporation, that the individual's conduct was in its best interests and (b) in all other cases, that the individual's conduct was at least not opposed to its best interests; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in the case of any criminal proceeding, the individual had no reasonable cause to believe the individual's
conduct was unlawful.

Notwithstanding the foregoing, a Washington corporation may not indemnify a director under RCW 23B.08.510 in connection with (a) a proceeding by or on behalf of the corporation in which the director was adjudged liable to the corporation or (b) any other proceeding charging improper personal benefit to the director, in which the director was adjudged liable on the basis that personal benefit was improperly received by the director. Additionally, where a proceeding is by or on behalf of the corporation, the indemnification permitted under RCW 23B.08.510 is limited to reasonable expenses incurred in connection with the proceeding.

RCW 23B.08.520 mandates a Washington corporation to indemnify a director who was wholly successful, on the merits or otherwise, in the defense of any proceeding to which the director was a party because of being a director of the corporation against reasonable expenses incurred by the director in connection with the proceeding, unless such indemnification is limited in the corporation's articles of incorporation. Our amended and restated articles of incorporation do not contain any such limitation.

RCW 23B.08.540 permits court-ordered indemnification, unless a corporation's articles of incorporation provide otherwise. Pursuant to this provision, in the absence of a contrary provision in a corporation's articles of incorporation, a director who is a party to a proceeding may apply for indemnification or advance of expenses to the court conducting the proceeding or to another court of competent jurisdiction, and such court may order indemnification or advance of expenses if it makes certain determinations.

Under RCW 23B.08.570, unless a corporation's articles of incorporation provide otherwise, an officer of a Washington corporation who is not a director is also entitled to mandatory indemnification under RCW 23B.08.520 and court-ordered indemnification under RCW 23B.08.540, each of which sections are summarized above, to the same extent as a director. Further, a Washington corporation may indemnify an officer, employee or agent of the corporation under RCW 23B.08.510, to the same extent as a director.

RCW 23B.08.580 permits a corporation to purchase and maintain insurance on behalf of any individual who is or was a director, officer, employee or agent of the corporation, or who while a director, officer, employee or agent of the corporation, is or was serving at the corporation's request as a director, officer, partner, trustee, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against liability asserted against or incurred by the individual in that capacity or arising from the individual's status as a director, officer, employee or agent, whether or not the corporation would have power to indemnify such individual against the same liability under RCW 23B.08.510 and 23B.08.520.

Our amended and restated articles of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted under Washington law.

We have entered into indemnification agreements with certain of our current directors and executive officers, and may enter into indemnification agreements with future directors and executive officers, to provide such directors and officers, additional contractual assurances regarding the scope of the indemnification set forth in our amended and restated articles of incorporation and our amended and restated bylaws and to provide additional procedural protections.

We may also purchase and maintain liability insurance on behalf of our directors, officers, employees and agents. We currently maintain a liability insurance policy pursuant to which our directors and officers may be indemnified against liability incurred as a result of serving in their capacities as directors and officers, subject to certain exclusions, including liabilities under the Securities Act.

------

**Item 7. Exemption from Registration Claimed.** 

Not applicable.

**Item 8. Exhibits.** 

The following Exhibits are being filed as part of this Registration Statement:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit<br>Number** | **Exhibit Title** | **Filed/Furnished<br>Herewith** | **Form** | **File No.** | **Exhibit** | **Filing<br>Date** |
| 4.1 | [Amended and Restated Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex31.htm) |  | 8-K | 001-38957 | 3.1 | 7/1/2019 |
| 4.2 | [Amended and Restated Bylaws](http://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex32.htm) |  | 8-K | 001-38957 | 3.2 | 7/1/2019 |
| 5.1 | [Opinion of DLA Piper LLP (US)](d105844dex51.htm) | X |  |  |  |  |
| 23.1 | [Consent of DLA Piper LLP (US) (included in Exhibit 5.1)](d105844dex51.htm) | X |  |  |  |  |
| 23.2 | [Consent of Independent Registered Public Accounting Firm](d105844dex232.htm) | X |  |  |  |  |
| 99.1# | [Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder](http://www.sec.gov/Archives/edgar/data/1478320/000156459019031827/adpt-ex1012_196.htm) |  | 10-Q | 001-38957 | 10.12 | 8/13/2019 |
| 99.2# | [Form of Stock Option Agreement for Non-U.S. Participants](http://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1016_340.htm) |  | 10-K | 001-38957 | 10.16 | 2/24/2021 |
| 99.3# | [Form of Restricted Stock Unit Agreement for Non-U.S. Participants](http://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1017_339.htm) |  | 10-K | 001-38957 | 10.17 | 2/24/2021 |
| 99.4# | [Form of Performance Units Agreement and Notice of Grant of Performance Units](http://www.sec.gov/Archives/edgar/data/0001478320/000156459022017870/adpt-ex101_95.htm) |  | 10-Q | 001-38957 | 10.1 | 5/4/2022 |
| 107 | [Filing Fees Table](d105844dexfilingfees.htm) | X |  |  |  |  |

---

# Indicates management contract or compensatory plan.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this 27th day of February, 2026.

---

| | |
|:---|:---|
| **Adaptive Biotechnologies Corporation** | **Adaptive Biotechnologies Corporation** |
| By: | */s/ Chad Robins* |
|  | Chad Robins |
|  | *Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Chad Robins and Kyle Piskel and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Chad Robins<br> Chad Robins | Chief Executive Officer and Director<br> *(Principal Executive Officer)* | February 27, 2026 |
| /s/ Kyle Piskel<br> Kyle Piskel | Chief Financial Officer<br> *(Principal Financial Officer and Principal Accounting Officer)* | February 27, 2026 |
| /s/ Michelle Griffin<br> Michelle Griffin | Director | February 27, 2026 |
| /s/ Robert Hershberg<br> Robert Hershberg, PhD, MD | Director | February 27, 2026 |
| /s/ Peter Neupert<br> Peter Neupert | Director | February 27, 2026 |
| /s/ Katey Owen<br> Katey Owen, PhD | Director | February 27, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g105844g0226081723457.jpg) | ***DLA Piper LLP (US)*** |
| ![LOGO](g105844g0226081723457.jpg) | 701 Fifth Avenue |
| ![LOGO](g105844g0226081723457.jpg) | Suite 6900 |
| ![LOGO](g105844g0226081723457.jpg) | Seattle, Washington 98104-7044<br> www.dlapiper.com |

---

February 27, 2026

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East

Seattle, Washington 98109

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Adaptive Biotechnologies Corporation, a Washington corporation (the "Company"), in connection with the registration on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), of up to 14,943,083 shares of Common Stock, par value $0.0001 per share (the "Shares"), reserved for issuance under the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan (the "Plan").

This opinion is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

We have examined such instruments, documents and records as we deemed relevant and necessary for the basis of our opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to the originals of all documents submitted to us as copies. As to matters of fact relevant to our opinion set forth below, we have relied, without independent investigation, on certificates of public officials and of officers of the Company. We express no opinion concerning any law other than the laws of the State of Washington.

On the basis of the foregoing, we are of the opinion that, when the Shares are issued and paid for in accordance with the terms of the Plan, they will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, or the Registration Statement. This opinion is rendered as of the date hereof, and we assume no obligation to advise you of any fact, circumstance, event or development that may hereafter be brought to our attention whether or not such occurrence would alter, affect or modify the opinion expressed herein.

Very truly yours,

/s/ DLA Piper LLP (US)

DLA PIPER LLP (US)

## Exhibit 23.2

**Exhibit 23.2** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan of our reports dated February 26, 2026, with respect to the consolidated financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation included in this Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Seattle, Washington

February 26, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Adaptive Biotechnologies Corp**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share, reserved for issuance pursuant to the 2019 Equity Incentive Plan | Other | 14943083 | $15.12 | $225939414.96 | 0.0001381 | $31202.23 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $225939414.96  |  | $31202.23  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $31202.23  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding shares of common stock. (2) Reflects automatic annual increases on each of January 1, 2024 and January 1, 2026 to the number of shares of the Registrant's common stock reserved for issuance under the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan (the "2019 EIP"), which annual increases are provided for in the 2019 EIP. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) under the Securities Act on the basis of $15.12 per share, which represents the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Global Select Market on February 23, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---